Table 1.

Baseline characteristics and outcomes after intervention.

Variables	Baduanjin group(n = 27)	Usual physical activity group(n = 27)	T value (χ2)	p value
Gender (male/female)	13/14	10/17	0.682	0.409
Age (years)	65.59 ± 9.16	60.48 ± 11.52	−1.805	0.077
Years of education (years)	7.07 ± 4.67	7.52 ± 3.84	0.382	0.704
Disease duration (years)	4.59 ± 3.70	7.56 ± 7.95	1.757	0.087
H-Y stage(pre-test)	2.57 ± 0.57	2.56 ± 0.56	−0.121	0.904
LEDDs(mg)	387.63 ± 193.25	553.13 ± 397.58	1.945	0.057
PPT (pre-test)
Dominant hand	9.15 ± 2.501	9.25 ± 2.048	0.158	0.875
Non-dominant hand	8.15 ± 2.556	7.77 ± 2.259	−0.583	0.562
Both hand	13.04 ± 4.148	13.95 ± 4.336	0.791	0.432
Assembly	18.23 ± 8.232	15.78 ± 6.315	−1.231	0.224
MDS-UPDRS III (pre-test)	40.67 ± 16.964	38.52 ± 16.023	−0.478	0.634
PDQ-39 (pre-test)	37.07 ± 20.147	44.93 ± 22.518	1.350	0.183
PPT (post-test)
Dominant hand	10.31 ± 2.456	9.17 ± 2.192	−1.792	0.079
Non-dominant hand	9.37 ± 2.532	7.75 ± 2.310	−2.449	0.018*
Both hand	15.14 ± 4.055	14.17 ± 4.346	−0.841	0.404
Assembly	20.47 ± 7.714	15.76 ± 6.316	−2.452	0.018*
MDS-UPDRS III (post-test)	36.48 ± 16.225	38.30 ± 16.231	0.411	0.683
PDQ-39(post-test)	33.07 ± 19.873	45.04 ± 22.243	2.084	0.042*

Means and standard deviations are shown for continuous variables.

Abbreviations: H-Y stage, Hoehn and Yahr stage; LEDDs, levodopa-equivalent daily doses; PPT, Purdue pegboard test; MDS-UPDRS III, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale, Part III (motor examination); PDQ-39, Parkinson’s Disease Questionnaire-39. *P < 0.05.